BioLineRx Ltd. (BLRX) - Quarterly EPS earnings growth

Official company branding of BioLineRx (BLRX)

BioLineRx Ltd. (BLRX) is implementing ESG principles by reducing laboratory waste and adhering to research ethics. Tracking quarterly EPS growth demonstrates operational dynamics, where the indicator value stands at 31.10. Financial stability is based on the launch of the approved drug. Meanwhile, the issuer's success relies on the expansion rate of the stem cell mobilization drug and the control of US marketing costs.

BioLineRx (BLRX) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for BioLineRx Ltd.

- market value and analyst target forecast:
Price Chart BioLineRx|BLRX - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization BioLineRx Corp|BLRX - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share BioLineRx|BLRX - Total Stockholders' Equity|Market Value to Book Value Ratio biolinerx.com|BLRX - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity BioLineRx Ltd.|BLRX - Long-Term Liabilities to Capital|Short-Term Debt to Capital BioLineRx Ltd.|BLRX - Company Total Indebtedness|Debt to Book Value BioLineRx Corp|BLRX - Long-Term Debt|Company Current Liabilities BioLineRx|Quick Liquidity Indicator biolinerx.com
- earnings and market multiples details:
BLRX - Profit After Payment of Taxes|Projected Future Earnings BioLineRx Ltd.|BLRX - Company Value to Net Income|Forward P/E Multiple BioLineRx Corp|BLRX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioLineRx Corp|BLRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BioLineRx|BLRX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biolinerx.com|BLRX - Earnings per share trend in current year|Expected earnings per share growth for next year BioLineRx Ltd.
Fundamental company analysis:BioLineRx, BLRX
Manufactured product of BioLineRx Corporation

Strategic alliances between BioLineRx Ltd. (BLRX) and pharmaceutical behemoths to bring cancer therapies to market determine the monetization potential of their developments. By analyzing the quarterly EPS trend, an investor assesses the percentage change in net income per share relative to the previous period, which allows for determining the efficiency of transforming operational successes into real income and evaluating the risks of capital impairment over the long term.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (cellectar.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com